key: cord-0710747-uzakgfat
authors: Chen, Qi; Huang, Xing‐Yao; Liu, Yu; Sun, Meng‐Xu; Ji, Bin; Zhou, Chao; Chi, Hang; Zhang, Rong‐Rong; Luo, Dan; Tian, Ying; Li, Xiao‐Feng; Zhao, Hui; Qin, Cheng‐Feng
title: Comparative characterization of SARS‐CoV‐2 variants of concern and mouse‐adapted strains in mice
date: 2022-03-30
journal: J Med Virol
DOI: 10.1002/jmv.27735
sha: 14c294f5dabc84089aa88a808d3a18221f3b2136
doc_id: 710747
cord_uid: uzakgfat

SARS‐CoV‐2 has evolved into a panel of variants of concern (VOCs) and constituted a sustained threat to global health. The wildtype (WT) SARS‐CoV‐2 isolates fail to infect mice, while the Beta variant, one of the VOCs, has acquired the capability to infect standard laboratory mice, raising a spreading risk of SARS‐CoV‐2 from humans to mice. However, the infectivity and pathogenicity of other VOCs in mice remain not fully understood. In this study, we systematically investigated the infectivity and pathogenicity of three VOCs, Alpha, Beta, and Delta, in mice in comparison with two well‐understood SARS‐CoV‐2 mouse‐adapted strains, MASCp6 and MASCp36, sharing key mutations in the receptor‐binding domain (RBD) with Alpha or Beta, respectively. Our results showed that the Beta variant had the strongest infectivity and pathogenicity among the three VOCs, while the Delta variant only caused limited replication and mild pathogenic changes in the mouse lung, which is much weaker than what the Alpha variant did. Meanwhile, Alpha showed comparable infectivity in lungs in comparison with MASCp6, and Beta only showed slightly lower infectivity in lungs when compared with MASCp36. These results indicated that all three VOCs have acquired the capability to infect mice, highlighting the ongoing spillover risk of SARS‐CoV‐2 from humans to mice during the continued evolution of SARS‐CoV‐2, and that the key amino acid mutations in the RBD of mouse‐adapted strains may be referenced as an early‐warning indicator for predicting the spillover risk of newly emerging SARS‐CoV‐2 variants.

the world, featured with seven substitutions and three deletions in Spike (S) protein, including N501Y in the receptor-binding domain (RBD). 3 Following the appearance of Alpha, the variant Beta was announced in South Africa in December 2020 and then detected in more than 140 countries within a few months, characterized by eight mutations in S protein, including K417N, E484K, and N501Y in RBD. 4 Among the co-circulating strains, the proportion of these two variants peaked in February to April 2021, at which the variant Delta began to appear in India, featured with E484Q and L452R mutations in S protein. 1, 5 In a short period, the variant Delta spread quickly across the globe and became the most dominant strain worldwide. 6 These mutations that occurred in the RBD of SARS-CoV-2 S protein are especially concerning, as the RBD is responsible for inducing neutralizing antibodies and mediating virus entry into host cells. The WT SARS-CoV-2 cannot effectively infect laboratory standard mice, because its RBD has a low binding affinity to mACE2. 7, 8 However, we recently found that the Beta variant has acquired the capability to infect laboratory standard mice, which is mainly caused by the mutations in the RBD, reminding us of the spreading risk of SARS-CoV-2 from humans to mice. 5 What's worse, some preliminary results from biochemical assay and pseudoviruses indicate that the RBD of other VOCs, even including those sharing no mutations with the RBD of Beta variant, also showed increased binding affinity to mACE2, [9] [10] [11] [12] [13] indicating it is necessary to further confirm whether these VOCs are also capable of infecting mice and causing spillover risk.

Herein, in this study, we sought to determine the infectivity and pathogenicity of three major VOCs, Alpha, Beta, and Delta, in mice. In previous studies, we and others developed several SARS-CoV-2 mouse-adapted strains by serially passaging of prototype SARS-CoV-2 strains in mice, which can effectively infect mice and cause pathological changes. 9, [14] [15] [16] [17] [18] [19] The mouse infectivity of these mouseadapted strains has been demonstrated to be largely related to the amino acid mutations identified in the RBD. By alignment, we found that among all the reported mouse-adapted strains, only MASCp6 and MASCp36 share key mutations in S protein with Alpha or Beta, respectively. Thus, in this study, we chose these two mouse-adapted strains as references for evaluating the infectivity and pathogenicity of VOCs. 

Nine-month-old female BALB/c mice were from Beijing Vital River Laboratory Animal Technology Co., Ltd. The SARS-CoV-2 strain BetaCov/human/CHN/Beijing_IME-BJ05/2020 (IME-BJ05, accession no. GWHACAX01000000) was used as the WT SARS-CoV-2 in this study. 5 The Alpha variant (C-Tan-BJ202101) was from the Chinese Center for Disease Control and Prevention. The Beta variant (GDPCC, CSTR: 16698.06.NPRC2.062100001) was from the National Pathogen Resource Center. 20 The Delta variant (CCPM-B-V-049-2105-8) was from the Chinese Academy of Medical Sciences.

The mouse-adapted strains MASCp6 and MASCp36 were generated by serial passaging in our previous studies. 9,14 These viruses were titrated by a standard plaque assay in Vero cells.

Mice were first anesthetized with sodium pentobarbital at a dose of 50 mg/kg through the intraperitoneal route, and then intranasally infected with 2.4 × 10 3 PFU of each SARS-CoV-2 strain (n = 9) or the same volume of Phosphate Buffered Saline (PBS) (mock, n = 3). Three mice in each group were then killed on Days 1−3 post-infection for tissue processing.

Lung and tracheahomogenates were centrifuged at 6000 rpm for 6 min for supernatant collection. Viral RNA in the supernatants was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturer's protocol. sgRNA in each sample was quantified by reverse transcription-quantitative real-time PCR (RT-qPCR) (using One Step PrimeScript RT-PCR Kit (Takara) with the following primers and probes targeting the S gene of SARS-CoV-2: sgRNA-F (5'-C GATCTCTTGTAGATCTGTTCTC-3'); sgRNA-R (5'-ATATTGCAGCAG TACGCACACA-3'); and sgRNA-P3 (5'-ACACTAGCCATCCTTACT GCGCTTCG-3'). 

The deparaffinized sections were stained with H&E and examined by light microscopy. The semiquantitative assessment was performed as follows. 14 For the degree of degeneration of alveolar epithelial cells and bronchiolar epithelial cells, we scored 0 when no cell degeneration was observed, scored 1 when the cell degeneration was less than 10% and scored 2 when the degeneration was 10%-50%. For the degree of alveolar septal thickening, we scored 0 when no alveolar septal thickening was observed, scored 1 when the alveolar septal thickening area was less than 10%, scored 2 when the area was 10%-20%, scored 3 when the area was 20%-50%, scored 4 when the area was >50%, and a score of 1 was added when alveolar wall fusion area was less than 10%, a score of 2 was added when the area was 10%-20%, and a score of 3 was added when the area was 20%-50%, and a score of 4 was added when the area was >50%. For the degree of edema, we scored 0 when no edema was observed, scored 1 when occasional edema was visible, and scored 2 when the edema was seen for 10%-50% of vascular, scored 3 when the edema was seen for >50% of vascular. For the degree of inflammatory cells infiltration, we scored 0 when no inflammatory cell infiltration, scored 1 when occasional infiltration of a single inflammatory cell was visible and scored 2 when focal infiltration of inflammatory cells was visible. For the degree of hemorrhage, we scored 0 when no hemorrhage was observed, scored 1 when occasional hemorrhage was visible and scored 2 when focal hemorrhage was visible. For the degree of bronchial epithelial cell damage and bronchial obstruction, we scored 0 when no bronchial epithelial cell damage was observed, scored 1 when occasional bronchial epithelial cell damage was visible and scored 2 when the epithelial cell damage was seen for 10%-20% of bronchi, scored 3 when the epithelial cell damage was seen for 20%-50% of bronchi, scored 4 when the epithelial cell damage was seen for >50% of bronchi, and a score of 1 was added when the occasional bronchial obstruction was observed, a score of 2 was added when it was observed for 10%-20% of bronchi, a score of 3 was added when it was seen for 20%-50% of bronchi. The lesion of the lung was observed by an experienced experimental pathologist who focuses on the pathogenesis study of virus infection, and the average of the three animals was taken as the total score for that group.

Tissue homogenates were centrifuged at 6000 rpm for 6 min for supernatant collection. The supernatants were then inactivated at 56°C for 60 min. Twenty-five microliters inactivated supernatants from each mouse was adopted for cytokine analysis with Mouse 

The S protein of the three VOCs was aligned with all the reported SARS-CoV-2 mouse-adapted strains. 9,14-19 As shown in Figure 1 Figure 4A,B) . In comparison, 18 cytokines were elevated to higher levels in Alpha-infected mice (Figures 4A and S1 ). As we expected, the Beta induced the strongest inflammatory response among the three VOCs: 33 out of the 36 detected cytokines were obviously elevated, and more than 20 cytokines were elevated more than 10 times ( Figure 4A ). These results indicate that Delta infection can only induce a slight inflammatory response, which is much weaker than that induced by the variant Alpha, while the Beta variant is able to induce the strongest inflammatory response among the three VOCs. It seems that the inflammatory response induced by these variants is positively associated with the virus replication in the lungs of infected mice. However, interestingly, Alpha infection elevated higher levels of cytokine production in comparison with MASCp6 ( Figures 4A and S1 ), despite they produced similar levels of sgRNA in the lung tissues as mentioned above (Figure 2A) , indicating that viral replication have obtained the infectivity in mice, worth being further investigated. Thus, in this study, we adopted three VOCs, Alpha, Beta, and Delta, to systematically investigate their infectivity and pathogenicity for mice, and confirmed that all three VOCs are able to infect laboratory standard mice and cause pulmonary pathology, highlighting the ongoing risk of spillover from human to mice during the continued evolution of SARS-CoV-2.

By our study, it was found that the variant Alpha can effectively infect mice, and the infectivity is comparable with MASCp6. In our previous study, it has been demonstrated that the mutation N501Y can effectively enhance the binding affinity of the RBD to mACE2, and play a key role in the infectivity of the mouse-adapted strain Despite the RBD of Delta having a lower binding affinity to mACE2 than the RBD of Alpha or Beta carrying the mutation N501Y, it still enables the variant to infect mice. Before our study, several studies demonstrated that the capability of the mutations L452R/ T478K to increase the infectivity of the SARS-CoV-2 pseudoviruses in mACE2-expressing cells was not as high as the mutation N501Y. 12, 13 Despite that, our study with the variant Delta in vivo clearly confirmed that the variant Delta still obtained the capability to infect mice, despite the infectivity being lower than the variants carrying the mutation N501Y. A recent study showed that no viral sgRNA was detected in Delta-infected C57/BL6 mice. 27 By comparison, we found that we adopted aged BALB/c mice (9-month-old) for challenging, whereas young C57/BL6 mice (8-week-old) were chosen in the previous study. Recently, it has been confirmed that the mouse-adapted strain was more virulent to BALB/c mice compared with the C57/BL6 mice, and more virulent to aged mice compared with the young ones. 9, 17, 19 Thus, the difference in mouse strain and age may be why no Delta sgRNA was detected in the previous study.

In consideration of the time-sequence of these three VOCs appeared, the infectivity for mice acquired by SARS-CoV-2 during its evolution in humans showed a first increased and then decreased trend. Despite the infectivity for mice did not keep increasing, the acquisition of infectivity for mice by all three VOCs indicates that the risk of SARS-CoV-2 spillover from humans to mice may not be a transient accidence. In fact, more and more mutations are confirmed to be able to render SARS-CoV-2 to infect mice, such as the newly emerged L452R and T478K in Delta, making the spillover risk more unpredictable and uncontrollable. Thus, the newly emerged variants shall be continuously monitored for their cross-species infectivity, and the related mutations in S protein, especially those in the RBD, are worth being further identified. Interestingly, by our study, it was confirmed that the mouse infectivity is comparable between the VOCs and mouse-adapted strains sharing key mutations in the RBD, indicating the key amino acid mutations in the RBD of mouseadapted strains may be referenced as an early-warning indicator for predicting the spillover risk of newly emerging SARS-CoV-2 variants, which may be helpful for easing the difficulty of monitoring measures mentioned above. In fact, another VOC, the Omicron, appeared after we have just finished this study. Despite we did not include this variant in this study, we made an alignment between the S genes of In this study, we adopted two mouse-adapted strains for infectivity and pathogenicity in comparison with VOCs, and found that the variant Alpha and mouse-adapted strain MASCp6 show comparable infectivity in lung tissues of infected mice, but Alpha induces a stronger inflammatory response. A recent study showed that SARS-CoV-2 exacerbates pro-inflammatory responses in myeloid cells not only through the interaction between the RBD and Tweety family member 2, but also through the interaction between the C-type lectin receptors and N-terminal domain (NTD)/C-terminal domain (CTD) of the S protein. 28 By comparison, another notable finding is that the tropism of the VOCs and mouse-adapted strains for the upper respiratory tract is not always positively associated with that for the lower respiratory tract. As we observed in this study, Alpha and MASCp6 showed similar infectivity in lung tissues, but MASCp6 showed higher infectivity in the trachea; Beta showed slightly lower infectivity in lung tissues but higher infectivity in the trachea when compared with

MASCp36. This phenomenon indicates that SARS-CoV-2 may change its tropism for the upper or lower respiratory tract during its evolution, which is in accordance with recent findings that the virus distribution in the respiratory tracts is obviously different between COVID-19 patients infected with recently emerged SARS-CoV-2 variants and prototype SARS-CoV-2. 29 Thus, our study may also provide a platform for investigating the mechanism of the tropism change of the newly emerged variants.

Our results confirmed that the spillover risk of SARS-CoV-2 from humans to mice may persistently exist during the continued 

The authors declare no conflicts of interest.

The data supporting the findings of the current study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0002-0632-2807

SARS-CoV-2 variants of concern are emerging in India

The biological and clinical significance of emerging SARS-CoV-2 variants

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Detection of a SARS-CoV-2 variant of concern in South Africa

Transient acquisition of crossspecies infectivity during the evolution of SARS-CoV-2

SARS-CoV-2 variants of concern

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor

Adaptation of SARS-CoV-2 in BALB/ c mice for testing vaccine efficacy

SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces typical pneumonia

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice

A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

The infection and pathogenicity of SARS-CoV-2 variant B.1.351 in hACE2 mice

SARS-CoV-2 variants of concern delta: a great challenge to prevention and control of COVID-19

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

SARS-CoV-2 variants, spike mutations and immune escape

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants expand species tropism to murines

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2

Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals

Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice